Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations.
about
Combination therapy versus celecoxib, a single selective COX-2 agent, to reduce gastrointestinal toxicity in arthritic patients: patient and cost-effectiveness considerations.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 August 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combination therapy versus cel ...... -effectiveness considerations.
@en
Combination therapy versus cel ...... -effectiveness considerations.
@nl
type
label
Combination therapy versus cel ...... -effectiveness considerations.
@en
Combination therapy versus cel ...... -effectiveness considerations.
@nl
prefLabel
Combination therapy versus cel ...... -effectiveness considerations.
@en
Combination therapy versus cel ...... -effectiveness considerations.
@nl
P2860
P356
P1476
Combination therapy versus cel ...... -effectiveness considerations.
@en
P2093
Gurkirpal Singh
Marina Scolnik
P2860
P356
10.2147/OARRR.S14568
P577
2011-08-03T00:00:00Z